Shanghai Henlius Biotech, Inc. (2696.HK)
| Previous close | 16.600 |
| Open | 16.900 |
| Bid | 16.460 x N/A |
| Ask | 16.500 x N/A |
| Day's range | 16.340 - 17.000 |
| 52-week range | 9.600 - 17.020 |
| Volume | |
| Avg. volume | 237,715 |
| Market cap | 8.946B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | 15.24 |
| EPS (TTM) | 1.080 |
| Earnings date | 21 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.66 |
PR NewswireHenlius Trastuzumab Receives FDA Approval in the United States
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the company's business partner, Accord BioPharma Inc. (the U.S. specialty division of Intas Pharmaceuticals, Ltd.), has received approval from the United States Food and Drug Administration (FDA) for HERCESSI™ (HLX02, trastuzumab-strf, biosimilar to Herceptin® trade name: HANQUYOU in China and Zercepac® in Europe), a trastuzumab biosimilar self-developed and -manufactured by Henlius. The product has been approved in the United States (U.S.)
PR NewswireHenlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity
On April 17, 2024, Henlius (2696.HK) released its 2023 Environmental, Social and Governance (ESG) report (hereinafter referred to as "ESG report" or "report"). The report comprehensively discloses the Company's initiatives and achievements in promoting is sustainability management strategies in 2023 from five frontiers, namely product, talent, environment, society and corporate governance. It is the fifth ESG-related report released by Henlius.
PR NewswireHenlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved
Henlius (2696.HK) announced its 2023 annual results. During the reporting period, Henlius' revenue reached about RMB5.3949 billion, representing an increase of 67.8% YoY, and recorded a net profit of RMB546.0 million. This is the first time for Henlius to achieve full-year profits following the company's achievement of its first half-year profits in H1 2023. The full year of profitability is due to increasing commercial sales of the core products and expanding sales volume. Henlius' products ach
